Compare Goodyear Tire & Rubber Co (GT) vs Moderna, Inc. (MRNA) Price & Performance

The Goodyear Tire & Rubber Company (GT) trades at $4.75, down 1.28% with a bearish technical outlook. The stock shows attractive valuation metrics with P/E of 4.69 and P/B of 0.48, but faces fundamental challenges including negative net income margin of -14.37% and ROE of -63.93%. Recent earnings showed mixed results with Q2 2026 beating expectations despite a loss, while the company executes a restructuring strategy focusing on premium EV tires.

GT presents a high-risk opportunity with significant upside potential given the $8.00 consensus price target, but investors face substantial execution risks amid ongoing restructuring, declining revenues, and persistent losses. The bearish technicals and mixed analyst sentiment (34.62% buy rating) suggest cautious optimism dependent on successful turnaround execution and margin improvement.

Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.

While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.